Adults age 65 or older with untreated chronic lymphocytic leukemia

What we are studying

The purpose of this study is to compare the effects, good and/or bad, of a new drug, either alone or in combination with the drug rituximab, with the standard treatment for this disease. The standard treatment is chemotherapy with the drug bendamustine in combination with the drug rituximab. The effects on you and your leukemia will be looked at to find out which treatment is better. Both bendamustine and rituximab are approved by the FDA to treat chronic lymphocytic leukemia (your leukemia type), but the study drug is considered investigational. In this study, you will get either the study drug alone, or study drug with rituximab, or bendamustine with rituximab. If you are in the group that receives bendamustine with rituximab and your disease returns, you will have the option to receive the study drug.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 65 - 80

Eligibility Criteria

  • Chronic lymphocytic leukemia that has been treated

What is involved

  • 28-Day chemotherapy cycles as long as disease does not progress

Compensation

None

Contact Information

Study Coordinator
Robin Harrelson
Email
rharrelso@wakehealth.edu
Phone
336-713-6924

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.